Amaran Biotech is a CDMO (Contract Development & Manufacturing Organization) specializing in drug process development, analytical services and cGMP manufacturing of high-value biopharmaceuticals. Amaran Biotech’s state-of-the-art manufacturing facility is in the Hsinchu Biomedical Science Park and has been granted the PIC/S GMP certification from the TFDA since 2017. In 2020, Amaran Biotech strengthened its collaboration with OBI Pharma Inc. through stock-for-stock exchange and officially became a subsidiary of OBI Pharma. In 2022, Amaran Biotech introduced Taiwan’s first fully automated robotic aseptic filling line. In 2024, its Building C received the Green Building Certification from Taiwan’s Ministry of the Interior. In 2025, Amaran Biotech was honored with the “Bioprocessing Excellence in Taiwan” award at the Asia-Pacific Biopharma Excellence Awards, the “Best Fill-Finish” award at the Asia-Pacific Biologics CDMO Excellence Awards in Singapore, and the “Best CDMO in Automated Aseptic Filling” award at the Taiwan Biopharma Excellence Awards, all presented by IMAPAC.

As a leading CDMO, Amaran Biotech specializes in delivering high-value biopharmaceutical services. Our elite team demonstrates exceptional execution capabilities in process development, optimization, and clinical production. Leveraging cutting-edge technology and solid expertise, we continuously innovate to meet evolving industry demands. Amaran Biotech supports our clients, accelerates drug development, and advances human health. For more information, please visit: www.amaranbiotech.com